Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio ...

The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

Ocular Therapeutix and Eyepoint Pharmaceuticals are developing competing eye treatments, and the competition appears to be getting heated.

VIR-5500 ASCO GU update, VIR-5818 H2’26, ECLIPSE 1 Q4’26 + more hepatitis delta readouts. See more details here.

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for ...

Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% ...

Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With ...

The Clinical Research Transformation: Future Outlook 2026 conference opened today, Monday, in Riyadh. Organized by King Faisal Specialist Hospital and Research Centre (KFSHRC), it aims to advance ...

Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

Danaher Corporation delivered slightly better-than-expected annual earnings, with conservative 2026 guidance that likely ...